CHARACTERISTICS OF PROLIFERATION AND INTERCELLULAR ADHESION IN PRE-CANCEROUS AND MALIGNANT EPITHELIAL SKIN TUMORS

Cover Page


Cite item

Full Text

Abstract

Background: Differential diagnostics between actinic keratosis which is one of pre-cancerous skin diseases, and intra-epidermal squamous cell skin cancer (or Bowen's disease) could be difficult in some cases even with morphological examination. The study on molecular characteristics of pre-cancerous skin disorders would allow for more accurate diagnostics and assessment of prognosis. Aim: To study proliferative activity of keratinocytes and E-cadherin expression on cell membranes in actinic keratosis and in Bowen's disease, with identification of differential diagnostic criteria. Materials and methods: We performed an immunohistochemistry study with anti-Ki-67 and anti-Е-cadherin monoclonal antibodies in skin bioptates of 23 patients with actinic keratosis and 10 patients with Bowen's disease. Results: The mean proliferation index in actinic keratosis without the bowen-like loci was 30.9 ± 11.4% (range, from 11.5 to 48.4%), and in actinic keratosis with the bowen-like loci, 40.3 ± 8.6% (range, from 31 to 57.6%). In both groups, E-cadherin expression in all cases (100%) was located in cell membranes. The mean proliferation index in Bowen's disease was 44.7 ± 8.2% (range, from 33.3 to 60%). In 48.2% of Bowen cells, abnormal type of E-cadherin expression (reduced membranous, membranous and cytoplasmatic and cytoplasmatic only). Conclusion: Actinic keratosis and Bowen's disease represent different stages of one and the same malignant process that have different proliferative cell activity and E-cadherin expression, which could be used as differential diagnostic markers.

About the authors

A. N. Khlebnikova

I.M. Sechenov First Moscow State Medical University; 8/2 Trubetskaya ul., Moscow, 119991, Russian Federation

Author for correspondence.
Email: alb9696@yandex.ru
MD, PhD, Professor, Chair of Skin and Venereal Diseases, Institute for Professional Education Russian Federation

L. E. Gurevich

Moscow Regional Research and Clinical Institute (MONIKI); 61/2 Shchepkina ul., Moscow, 129110, Russian Federation

Email: alb9696@yandex.ru
MD, PhD, Leading Research Fellow, Department of Pathological Anatomy Russian Federation

E. V. Selezneva

I.M. Sechenov First Moscow State Medical University; 8/2 Trubetskaya ul., Moscow, 119991, Russian Federation

Email: alb9696@yandex.ru
MD, PhD, Assistant, Chair of Skin and Venereal Diseases, Institute for Professional Education Russian Federation

K. V. Obydenova

Moscow Regional Research and Clinical Institute (MONIKI); 61/2 Shchepkina ul., Moscow, 129110, Russian Federation

Email: alb9696@yandex.ru
MD, PhD Student, Chair of Dermatovenereology and Dermato-Oncology, Postgraduate Training Faculty Russian Federation

T. G. Sedova

Perm State Medical Academy named after academician E.A.Vagner; 26 Petropavlovskaya ul., Perm, 614990, Russian Federation

Email: alb9696@yandex.ru

MD, PhD, Associate Professor, Chair of Dermatology and Venereology

Russian Federation

Zh. S. Kuntsevich

Moscow Regional Research and Clinical Institute (MONIKI); 61/2 Shchepkina ul., Moscow, 129110, Russian Federation

Email: alb9696@yandex.ru
MD, PhD, Associate Professor, Chair of Dermatovenereology and Dermato-Oncology, Postgraduate Training Faculty Russian Federation

References

  1. Marks R. The epidemiology of non-melanoma skin cancer: who, why and what can we do about it. J Dermatol. 1995;22(11):853–7.
  2. Housman TS, Feldman SR, Williford PM, Fleischer AB Jr, Goldman ND, Acostamadie-do JM, Chen GJ. Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol. 2003;48(3):425–9.
  3. Marks R, Foley P, Goodman G, Hage BH, Sel-wood TS. Spontaneous remission of solar keratoses: the case for conservative management. Br J Dermatol. 1986;115(6):649–55.
  4. Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet. 1988;1(8589):795–7.
  5. Dodson JM, DeSpain J, Hewett JE, Clark DP. Malignant potential of actinic keratoses and the controversy over treatment. A patient-oriented perspective. Arch Dermatol. 1991;127(7):1029–31.
  6. McCabe M, Nowak M, Maguire D, Robert-son P. Immunosuppression by human skin cancers. Aust J Exp Biol Med Sci. 1984;62 (Pt 5):539–45.
  7. Молочков ВА. Плоскоклеточный рак кожи. Вестник дерматологии и венерологии. 1997;(6):44–8.
  8. Cockerell CJ, Wharton JR. New histopathological classification of actinic keratosis (incipient intraepidermal squamous cell carcinoma). J Drugs Dermatol. 2005;4(4):462–7.
  9. Elder DE, Elenitsas R, Johnson BL Jr, Murphy GF, eds. Lever's Histopathology of the Skin. 9th Edition. Philadelphia: Lippincott Williams & Wilkins; 2005. 645 p.
  10. Bagazgoitia L, Cuevas J, Juarranz A. Expression of p53 and p16 in actinic keratosis, bowenoid actinic keratosis and Bowen's disease. J Eur Acad Dermatol Venereol. 2010;24(2):228–30. doi: 10.1111/j.1468-3083.2009.03337.x.
  11. Hashimoto K, Mehregan AH. Tumors of the epidermis. Stoneham: Butterworth; 1990.
  12. Ishida H, Kumakiri M, Ueda K, Lao LM, Yanagihara M, Asamoto K, Imamura Y, Noriki S, Fukuda M. Comparative histochemical study of Bowen's disease and actinic keratosis: preserved normal basal cells in Bowen's disease. Eur J Histochem. 2001;45(2):177–90.
  13. Carpenter PM, Linden KG, McLaren CE, Li KT, Arain S, Barr RJ, Hite P, Sun JD, Meyskens FL Jr. Nuclear morphometry and molecular bio-markers of actinic keratosis, sun-damaged, and nonexposed skin. Cancer Epidemiol Bio-markers Prev. 2004;13(12):1996–2002.
  14. Tilli CM, Ramaekers FC, Broers JL, Hutchison CJ, Neumann HA. Lamin expression in normal human skin, actinic keratosis, squamous cell carcinoma and basal cell carcinoma. Br J Dermatol. 2003;148(1):102–9.
  15. Talghini S, Halimi M, Baybordi H. Expression of p 27, Ki 67, p 53 in squamous cell carcinoma, actinic keratosis and Bowen disease. Pakistan Journal of Biological Sciences. 2009;12(12):929–33. doi: 10.3923/ pjbs.2009.929.933.
  16. Lyakhovitsky A, Barzilai A, Fogel M, Trau H, Huszar M. Expression of e-cadherin and beta-catenin in cutaneous squamous cell carcinoma and its precursors. Am J Dermatopathol. 2004;26(5):372–8.
  17. Papadavid E, Pignatelli M, Zakynthinos S, Krausz T, Chu AC. Abnormal immunoreactivity of the E-cadherin/catenin (alpha-, beta-, and gamma-) complex in premalignant and malignant non-melanocytic skin tumours. J Pathol. 2002;196(2):154–62.
  18. Fuller LC, Allen MH, Montesu M, Barker JN, Macdonald DM. Expression of E-cadherin in human epidermal non-melanoma cutaneous tumours. Br J Dermatol. 1996;134(1):28–32.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2016 Khlebnikova A.N., Gurevich L.E., Selezneva E.V., Obydenova K.V., Sedova T.G., Kuntsevich Z.S.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies